In the present manuscript, patients with CBF‐AML and patients who further had better minimal residual disease (MRD) reduction (≥3‐log) after induction chemotherapy had higher tendency to develop HLA‐I antibodies and PTR. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.